November 29, 2022

Dr Rahul Kushwah on infectious disease symptom screening technology, sales and the Predictmedix partnerships in play

In a recent InvestorIntel interview, Tracy Weslosky speaks with Dr. Rahul Kushwah, Co-Founder and COO of Predictmedix Inc. (CSE: PMED | OTCQB: PMEDF) about ramping up their sales and business development efforts and provides an update on partnerships already in play.

Predictmedix is dedicated to health and wellness using artificial intelligence powered technologies. In this InvestorIntel interview, which may also be viewed on YouTube (click here to subscribe to the InvestorIntel Channel), Dr. Kushwah went on to provide an update on the Safe Entry Stations powered by Predictmedix’s proprietary infectious disease symptom screening technology. “We have had successful deployment with several companies including Fortune 500 companies such as Indian Oil,” Dr. Kushwah said.

Predictmedix has been actively signing partnerships with some of the major healthcare providers. “We have partnered with Max Healthcare which is one of the largest groups of hospitals in Asia…At the same time we have just deployed our technology at MGM Hospital in Mumbai and that is one of the largest COVID-19 clinics in India.”

To watch the full interview, click here

About Predictmedix Inc.

Predictmedix Inc. is an artificial intelligence (“AI”) company developing disruptive tools for impairment testing and healthcare. It is intended that the Company’s cannabis and alcohol impairment detection tools will be used across various workplaces and by law enforcement agents. Its technology uses facial and voice recognition to identify both cannabis and alcohol impairment by utilizing multiple features along with numerous different data points. Testing does not require any body fluids or human intervention, thereby helping to remove human error and the potential for discrimination and prejudice.

The Company is also developing AI based screening for the healthcare industry. The recent advent of COVID-19 pandemic has placed unprecedented stress on the global economy and highlights the need for tools to help screen mass populations for infectious diseases, with the hope of preventing pandemics in the future. In turn, Predictmedix Inc. is expanding its proprietary AI technology to screen for infectious disease symptoms.

Additionally, psychiatric disorders such as depression, dementia and Alzheimer’s disease can carry a significant burden and early identification is the key to better management. To help address this, the Company is also expanding its proprietary AI technology to screen for psychiatric and/or brain disorders such as depression, dementia and Alzheimer’s disease.

To learn more about Predictmedix Inc., click here

Disclaimer: Predictmedix Inc. is an advertorial member of InvestorIntel Corp.

Disclaimer: The author of this post may or may not be a shareholder of any of the companies mentioned in this column. None of the companies discussed in the above feature have paid for this content. The writer of this article/post/column/opinion is not an investment advisor, and is neither licensed to nor is making any buy or sell recommendations. For more information about this or any other company, please review their public documents to conduct your own due diligence. To access the InvestorIntel.com disclaimer and other important legal notices, click here.

Leave a Reply

Your email address will not be published. Required fields are marked *